Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer’s Announcement
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Pfizer has just announced that a person with hemophilia, in their marstacimab (Hympavzi) clinical trial program, has died from a thrombotic stroke.
I attach the letter they sent to a number of patient organisations including the World Federation of Hemophilia.
The information provided in the letter is minimal.
I hope they reach out to all hemophilia doctors worldwide who can potentially prescribe this drug to inform them about this event, and the other thrombotic event in the same clinical trial that was previously disclosed at the EAHAD and ISTH meetings.
The patient who died, had hemophilia A with an inhibitor.
Marstacimab is at present only approved for persons with hemophilia A and B without an inhibitor.”
Stay updated with Hemostasis Today.
-
Jan 5, 2026, 15:33Mona Ahmed on Why Some Calcified Nodules Trigger ACS and Others Do Not
-
Jan 5, 2026, 14:17Abdul Mannan – VWF:RCo for Diagnosing von Willebrand Disease: That Test Might Be Failing Your Patients
-
Jan 5, 2026, 13:57Ewang Yemi: CAD is Real and Dangerous – Keep Your Heart Beating
-
Jan 5, 2026, 13:42Dr. Martha Boeckenfeld Shares VetiGel Creation Experiment: How A 17-Year-Old Mixed Algae in a Small Hidden Lab
-
Jan 5, 2026, 12:55Chokri Ben Lamine Explains Washed PRBCs!
-
Jan 5, 2026, 12:30ASH: Be Part of The Next Cohort of Hematology Quality Improvement Leaders
-
Jan 5, 2026, 09:59WFH Released New Evidence-Based Guidelines on AAV Gene Therapy for Hemophilia
-
Jan 5, 2026, 09:51Pete Stibbs: We Still Tend to Talk About VTE Like It’s a Plumbing Problem
-
Jan 5, 2026, 09:40Christopher Pittman on Treating Varicose Veins Before Knee or Hip Replacement